|
1
|
Umeda M, Komatsubara H, Nishimura N, Oku
N, Shibuya Y, Yokoo S and Komori T: Establishment and
characterization of a human adenoid cystic carcinoma line of the
salivary gland which is serially transplantable and spontaneously
metastasizes to the lung in nude mice. Oral Oncol. 38:30–34. 2002.
View Article : Google Scholar
|
|
2
|
Alleyne CH, Bakay RA, Costigan D, Thomas B
and Joseph GJ: Intracranial adenoid cystic carcinoma: case report
and review of the literature. Surg Neurol. 45:265–271. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
van der wal JE, Becking AG, Snow GB and
van der Wall I: Distant metastases of adenoid cystic carcinoma of
the salivary glands and the value of diagnostic examinations during
follow-up. Head Neck. 24:779–783. 2002.PubMed/NCBI
|
|
4
|
Mithani SK, Shao C, Tan M, Smith IM,
Califano JA, El-Naggar AK and Ha PK: Mitochondrial mutations in
adenoid cystic carcinoma of the salivary glands. PLoS One.
4:e84932009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Dodd RL and Slevin NJ: Salivary gland
adenoid cystic carcinoma: a review of chemotherapy and molecular
therapies. Oral Oncol. 42:759–769. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kawashima T, Kagawa S, Kobayashi N, et al:
Telomerase-specific replication-selective virotherapy for human
cancer. Clin Cancer Res. 10:285–292. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Taki M, Kagawa S, Nishizaki M, et al:
Enhanced oncolysis by a tropism-modified telomerase-specific
replication-selective adenoviral agent OBP-405 (‘Telomelysin-RGD’).
Oncogene. 24:3130–3140. 2005.PubMed/NCBI
|
|
8
|
Umeoka T, Kawashima T, Kagawa S, et al:
Visualization of intrathoracically disseminated solid tumors in
mice with optical imaging by telomerase-specific amplification of a
transferred green fluorescent protein gene. Cancer Res.
64:6259–6265. 2004. View Article : Google Scholar
|
|
9
|
Hashimoto Y, Watanabe Y, Shirakiya Y, et
al: Establishment of biological and pharmacokinetic assays of
telomerase-specific replication-selective adenovirus. Cancer Sci.
99:385–390. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bischoff JR, Kirn DH, Williams A, et al:
An adenovirus mutant that replicates selectively in p53-deficient
human tumor cells. Science. 274:373–376. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kishimoto H, Kojima T, Watanabe Y, et al:
In vivo imaging of lymph node metastasis with
telomerase-specific replication-selective adenovirus. Nat Med.
12:1213–1219. 2006. View
Article : Google Scholar
|
|
12
|
Kurihara Y, Watanabe Y, Onimatsu H, et al:
Telomerase-specific virotheranostics for human head and neck
cancer. Clin Cancer Res. 15:2335–2343. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
He RG, Qiu WL and Zhou XJ: The
establishment of Acc-2 and Acc-3 and their morphological
observation. J West China Stromatol. 6:1–3. 1986.
|
|
14
|
Guan XF, Qiu WL, He RG and Zhou XJ:
Selection of adenoid cystic carcinoma cell clone highly metastatic
to the lung: an experimental study. Int J Oral Maxillofac Surg.
26:116–119. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fujiwara T: A novel molecular therapy
using bioengineered adenovirus for human gastrointestinal cancer.
Acta Med Okayama. 65:151–162. 2011.PubMed/NCBI
|
|
16
|
Yasuda Y, Kondo S, Nagumo T, et al:
Anti-tumor activity of dehydroxymethylepoxyquinomicin against human
oral squamous cell carcinoma cell lines in vitro and in
vivo. Oral Oncol. 47:334–339. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sakakibara A, Tsukuda M, Kondo N,
Tsukamoto H, Mukudai Y, Umezawa K and Shintani S: Examination of
the optimal condition on the in vitro sensitivity to telomelysin in
head and neck cancer cell lines. Auris Nasus Larynx. 38:589–599.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kim NW, Piatyszek MA, Prowse KR, et al:
Specific association of human telomerase activity with immortal
cells and cancer. Science. 266:2011–2015. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shay JW and Bacchetti S: A survey of
telomerase activity in human cancer. Eur J Cancer. 33:787–791.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Dong CK, Masutomi K and Hahn WC:
Telomerase: regulation, function and transformation. Crit Rev Oncol
Hematol. 54:85–93. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kyo S, Takakura M, Kohama T and Inoue M:
Telomerase activity in human endometrium. Cancer Res. 57:610–614.
1997.PubMed/NCBI
|
|
22
|
Kyo S and Inoue M: Complex regulatory
mechanisms of telomerase activity in normal and cancer cells: how
can we apply them for cancer therapy? Oncogene. 21:688–697. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sasaki T, Tazawa H, Hasei J, et al:
Preclinical evaluation of telomerase-specific oncolytic virotherapy
for human bone and soft tissue sarcomas. Clin Cancer Res.
17:1828–1838. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li G, Kawashima H, Ogose A, et al:
Efficient virotherapy for osteosarcoma by telomerase-specific
oncolytic adenovirus. J Cancer Res Clin Oncol. 137:1037–1051. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fujiwara T, Kagawa S, Kishimoto H, et al:
Enhanced antitumor efficacy of telomerase-selective oncolytic
adenoviral agent OBP-401 with docetaxel: preclinical evaluation of
chemovirotherapy. Int J Cancer. 119:432–440. 2006. View Article : Google Scholar
|
|
26
|
Hioki M, Kagawa S, Fujiwara T, et al:
Combination of oncolytic adenovirotherapy and Bax gene therapy in
human cancer xenografted models. Potential merits and hurdles for
combination therapy. Int J Cancer. 122:2628–2633. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Nakajima O, Matsunaga A, Ichimaru D, Urata
Y, Fujiwara T and Kawakami K: Telomerase-specific virotherapy in an
animal model of human head and neck cancer. Mol Cancer Ther.
8:171–177. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yamasaki Y, Tazawa H, Hashimoto Y, et al:
A novel apoptotic mechanism of genetically engineered
adenovirus-mediated tumour-specific p53 overexpression through
E1A-dependent p21 and MDM2 suppression. Eur J Cancer. 48:2282–2291.
2012. View Article : Google Scholar
|
|
29
|
Hasei J, Sasaki T, Tazawa H, et al: Dual
programmed cell death pathways induced by p53 transactivation
overcome resistance to oncolytic adenovirus in human osteosarcoma
cells. Mol Cancer Ther. 12:314–325. 2013. View Article : Google Scholar
|
|
30
|
Nemunaitis J, Tong AW, Nemunaitis M, et
al: A phase I study of telomerase-specific replication competent
oncolytic adenovirus (telomelysin) for various solid tumors. Mol
Ther. 18:429–434. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Del Vecchio S, Zannetti A, Fonti R, Pace L
and Salvatore M: Nuclear imaging in cancer theranostics. Q J Nucl
Med Mol Imaging. 51:152–163. 2007.
|
